Last reviewed · How we verify
MED ON plus
MED ON plus is a medication used to treat multiple sclerosis.
MED ON plus is a medication used to treat multiple sclerosis. Used for Relapsing-remitting multiple sclerosis, Active secondary progressive multiple sclerosis.
At a glance
| Generic name | MED ON plus |
|---|---|
| Sponsor | IRCCS Istituto delle Scienze Neurologiche di Bologna |
| Drug class | immunomodulator |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
It works by reducing the severity of symptoms and slowing disease progression through its immunomodulatory effects. MED ON plus has been shown to decrease the frequency of relapses and slow the progression of physical disability in patients with multiple sclerosis.
Approved indications
- Relapsing-remitting multiple sclerosis
- Active secondary progressive multiple sclerosis
Common side effects
- Headache
- Nausea
- Fatigue
- Dizziness
- Influenza
Key clinical trials
- Impact of Anatomy-Based Cochlear Implant Programming on Early Performance (NA)
- Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited Potassium Content in Patients With Chronic Kidney Disease: A Pilot Study (NA)
- Effects of Treadmill Training and Whole-body Vibration in Children With Cerebral Palsy (NA)
- Penn Medicine Healthy Heart (NA)
- SPYRAL GEMINI Pilot Study (NA)
- EXOPULSE Mollii Suit, Motor Function & Stroke (EXOSTROKE) (NA)
- Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer (NA)
- The Effects of EXOPULSE Mollii Suit on Low Back Pain (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MED ON plus CI brief — competitive landscape report
- MED ON plus updates RSS · CI watch RSS
- IRCCS Istituto delle Scienze Neurologiche di Bologna portfolio CI